4.8 Review

Extracellular Vesicles and Circulating Tumour Cells-complementary liquid biopsies or standalone concepts

期刊

THERANOSTICS
卷 12, 期 13, 页码 5836-5855

出版社

IVYSPRING INT PUBL
DOI: 10.7150/thno.73400

关键词

CTC; extracellular vesicles; exosomes; microvesicles; ectosomes; biomarker; liquid biopsy; personalized medicine

资金

  1. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [410853455]
  2. Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy [EXC 2151-390873048]
  3. DFG [411345524]
  4. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)

向作者/读者索取更多资源

Liquid biopsies, as biomarkers in cancer diagnosis, have great potential but also limitations. This review focuses on comparing extracellular vesicles (EVs) and circulating tumor cells (CTCs) and discussing their similarities in characterization and quantification. While it is not concluded which is better between CTCs and EVs, the review provides reasons to intensify research on both.
Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn???t to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers??? attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据